| Genentech Gain Rights to Acquire Forma Therapeutics’ Preclinical Cancer Programme in Innovative Deal |
Abstract
|
|
Heather Cartwright |
|
| AstraZeneca and PTC Therapeutics Sign Cancer Drug Discovery Pact |
Abstract
|
|
Heather Cartwright |
|
| Rib-X Pharmaceuticals Signs Global Antibiotic Research Collaboration with Sanofi |
Abstract
|
|
Heather Cartwright |
|
| Micromet Signs US$1 B BiTE® Antibody Collaboration with Amgen |
Abstract
|
|
Heather Cartwright |
|
| Gilead and Tibotec Partner to Develop and Commercialise HIV Combination Drugs |
Abstract
|
|
Heather Cartwright |
|
| BMS Licenses Innate Pharma’s Phase I Immuno-Oncology Monoclonal Antibody |
Abstract
|
|
Heather Cartwright |
|
| Allozyne to Go Public via Reverse Merger with Poniard Pharmaceuticals |
Abstract
|
|
Heather Cartwright |
|
| Valeant to Buy Sanofi’s Dermik Skincare Unit for US$425 M |
Abstract
|
|
Heather Cartwright |
|
| Valeant Continues its Acquisition Spree with Agreement to Buy Janssen’s Ortho Dermatologics Division |
Abstract
|
|
Heather Cartwright |
|
| Allergan Agrees to Acquire Vicept Therapeutics in US$275 M Deal |
Abstract
|
|
Heather Cartwright |
|
| Roche Broadens its Cancer Diagnostics Portfolio with mtm laboratories Acquisition |
Abstract
|
|
Heather Cartwright |
|
| Astellas Divests Prosidion’s DPP-IV Inhibitor Patent Assets to Royalty Pharma |
Abstract
|
|
Heather Cartwright |
|